基于ATRAP/NOX4/ROS信号通路探讨益气通络方抑制血管内膜增生的作用机制OA
Mechanisms of Yiqi Tongluo Formula in inhibiting vascular intimal hyperplasia via the ATRAP/NOX4/ROS signaling pathway
目的 基于血管紧张素Ⅱ1型受体相关蛋白(ATRAP)/还原型烟酰胺腺嘌呤二核苷酸磷酸氧化酶4(NOX4)/活性氧(ROS)信号通路探究益气通络方抑制血管内膜增生的作用机制.方法 将大鼠按随机数字表法分为假手术组、空白组、模型组、阳性药物组及低、中、高剂量中药组,每组15只.除假手术组、空白组外,其他各组大鼠构建颈总动脉球囊损伤模型,假手术组仅结扎颈外动脉.假手术组、空白组、模型组不予药物干预.阳性药物组大鼠给予阿托伐他汀钙片1.02 mg/kg灌胃;低、中、高剂量中药组大鼠分别给予6、12、24 g/kg(生药)的益气通络方药液灌胃.均1次/d,共干预14 d.苏木精-伊红染色观察颈总动脉病理改变,测量切片中血管管腔面积(LA)、内弹力板以内面积(IELA)、外弹力板以内面积(EELA),计算血管内膜面积(IA)、中膜面积(MA)、IA/MA、内膜厚度(IT)、中膜厚度(MT)、内膜面积增生率(HRIA)、内膜厚度增生率(HRIT);ELISA法检测颈总动脉组织氧化应激相关指标ROS、丙二醛(MDA)、乳酸脱氢酶(LDH)、超氧化物歧化酶(SOD);免疫荧光染色检测颈总动脉中ATRAP、NOX4、22 kDa钙调相关蛋白(SM22α)、骨桥蛋白(OPN)蛋白表达;蛋白免疫印迹(WB)检测颈总动脉组织ATRAP、NOX4、SM22α、OPN、基质金属蛋白酶-9(MMP-9)、组织金属蛋白酶抑制剂-1(TIMP-1)蛋白表达.结果 与模型组比较,益气通络方各剂量组血管内膜增生程度减轻,IA、IT、HRIA、HRIT、ROS、LDH、MDA低(P<0.01),SOD高(P<0.01),ATRAP、SM22α、TIMP-1蛋白表达高(P<0.01),NOX4、OPN、MMP-9蛋白表达低(P<0.01).结论 益气通络方可调控ATRAP/NOX4/ROS信号通路,抑制血管平滑肌细胞(VSMCs)增殖与迁移,减轻氧化应激反应,调节TIMP-1与MMP-9的平衡,发挥抗血管内膜增生作用.
Objective To investigate the mechanisms by which Yiqi Tongluo Formula inhibits vascular intimal hyperplasia based on the angiotensin II type 1 receptor-associated protein(ATRAP)/NADPH oxidase 4(NOX4)/reactive oxygen species(ROS)signaling pathway.Methods Rats were randomly divided into a sham operation group,a blank group,a model group,a positive drug group,and low-,medium-,and high-dose Yiqi Tongluo Formula groups(n=15 each).Except for the sham operation and blank groups,all other groups underwent balloon injury of the common carotid artery to establish a vascular intimal hyperplasia model,and the sham operation group received ligation of the external carotid artery only.No drug intervention was given to the sham operation,blank,or model groups.The positive drug group received atorvastatin calcium tablets(1.02 mg/kg).The low-,medium-,and high-dose groups were administered Yiqi Tongluo Formula at doses of 6.0,12.0,and 24.0 g/kg(crude drug),respectively,once daily for 14 days.Hematoxylin-eosin staining was used to observe pathological changes in the common carotid artery.Luminal area(LA),area within the internal elastic lamina(IELA),and area within the external elastic lamina(EELA)were measured to calculate intimal area(IA),medial area(MA),IA/MA ratio,intimal thickness(IT),medial thickness(MT),intimal area hyperplasia rate(HRIA),and intimal thickness hyperplasia rate(HRIT).Oxidative stress-related indicators,including ROS,malondialdehyde(MDA),lactate dehydrogenase(LDH),and superoxide dismutase(SOD),were measured by ELISA.Immunofluorescence staining was used to detect protein expression of ATRAP,NOX4,smooth muscle 22α(SM22α),and osteopontin(OPN).Western blot was performed to assess the expression of ATRAP,NOX4,SM22α,OPN,matrix metalloproteinase-9(MMP-9),and tissue inhibitor of metalloproteinases-1(TIMP-1)in carotid artery tissues.Results Compared with the model group,all Yiqi Tongluo Formula groups showed reduced vascular intimal hyperplasia,with lower IA,IT,HRIA,HRIT,ROS,LDH,and MDA levels(P<0.01),and higher SOD levels(P<0.01).Protein expression of ATRAP,SM22α,and TIMP-1 was significantly increased(P<0.01),whereas expression of NOX4,OPN,and MMP-9 was significantly decreased(P<0.01).Conclusion Yiqi Tongluo Formula may inhibit vascular intimal hyperplasia by regulating the ATRAP/NOX4/ROS signaling pathway,suppressing vascular smooth muscle cell(VSMC)proliferation and migration,alleviating oxidative stress,and maintaining the balance between TIMP-1 and MMP-9.
李文京;王革生;袁健;李蕊萍;刘乙兴;王清华;郑粲;赵聪;蒋莉
北京中医药大学第二临床医学院,北京 100029北京中医药大学东方医院脑外科,北京 100078北京中医药大学第二临床医学院,北京 100029深圳市宝安区中医院针灸科,深圳 518101北京中医药大学第二临床医学院,北京 100029北京中医药大学第二临床医学院,北京 100029北京中医药大学第二临床医学院,北京 100029北京中医药大学第二临床医学院,北京 100029北京中医药大学第二临床医学院,北京 100029
益气通络方血管内膜增生血管平滑肌细胞表型转化血管紧张素Ⅱ1型受体相关蛋白/还原型烟酰胺腺嘌呤二核苷酸磷酸氧化酶4/活性氧信号通路
Yiqi Tongluo Formulavascular intimal hyperplasiavascular smooth muscle cellsphenotypic transformationangiotensin Ⅱ type 1 receptor-associated protein/NADPH oxidase 4/reactive oxygen species signaling pathway
《北京中医药》 2026 (2)
181-189,9
北京中医药大学2024年度揭榜挂帅项目(2024-JYB-JBZD-005)
评论